Morrisville, NC (PRWEB) June 28, 2010
Sicel Technologies, Inc., maker of the Dose Verification System (DVS), the world’s first and only wireless implantable dosimeter cleared for breast and prostate cancer treatment, today announced that it was joined by three independent healthcare professionals who use the technology in attending the American Society for Radiation Oncology (ASTRO) “Safety in Radiation Therapy” meeting, held June 24 to 25 in Miami.
Many at the ASTRO meeting, which followed the recent FDA conference on radiation therapy, offered suggestions for improvements that minimized distractions in the clinic and utilized ‘more timeout’ techniques for insuring compliance with a checklist to insure proper execution of procedures. Almost all speakers concurred there are no standards in the industry for reporting of near misses and incidents.
Peter Mondalek, PhD, Medical Physicist, Atlanta Oncology, challenged one of the panels with the question “Why not recommend an implantable dosimeter as the surest way of knowing the dose at the point of the tumor and assuring patient safety? With almost all of the meeting speakers suggesting that there are no industry standards for reporting of near misses and incidents, it is apparent that DVS remains the best way to correctly measure the actual dose provided to the tumor.”
Attending the meeting were many of the nation’s leading cancer centers. Among them were DVS users from Thomas Jefferson Medical Center, Philadelphia, and Lynn Regional Cancer Center, Boca Raton Fla.
“We are encouraged by comments at the recent meeting hosted by the AAPM and ASTRO, following the recent FDA meeting, will lead to significant changes in monitoring radiation therapy and reporting,” said Dr. Chuck Scarantino, Medical Director and co-founder of Sicel Technologies. “We firmly believe that DVS technology is the missing link relative to current treatment practices and safeguards meant to help protect patients during radiation therapy. The only way to know the dose is to measure the dose. DVS makes that information available at the tumor location.”
About the Dose Verification System
Sicel Technologies, Inc.’s, in vivo and in situ Dose Verification System® is first and only wireless, implantable dosimeter cleared by the U.S. FDA for the treatment of breast and prostate cancer that measures the amount of radiation that is delivered to the tumor tissue, tumor bed (where the tumor was) and/or healthy tissue. Wireless technology transmits the information to a hand-held monitor and radiation absorption rates are read during daily treatments, enabling healthcare professionals to verify that the patient is receiving the exact prescribed dose.
Traditional radiation therapies rely on knowing the exact location of the tumor, but provide no guidance on quantifying the actual radiation dose being delivered to the tumor. DVS offers the unique capability to use the device both for tumor localization and to verify the actual radiation dose delivered to the tumor and normal tissue for an unprecedented level of precision and added reassurance.
About Sicel Technologies, Inc.
Founded in 1999, and headquartered in Morrisville, North Carolina, Sicel Technologies, Inc., is a privately held, specialty device company focused on the development of revolutionary therapies that significantly impact the treatment of cancer—a leading cause of death in the U.S., second only to heart disease.
Recently voted one of the “Top 50 Companies To Watch” by Medical Device & Diagnostic Industry, Sicel Technologies, Inc., developed the Dose Verification System®, the first U.S. Food & Drug Administration-cleared wireless implantable sensors designed to assist clinicians in determining the actual dose of radiation being delivered to the tumor. The company also makes and markets OneDose™, patient dosimetry verification systems specifically designed for radiation oncology therapy.